Clinical trials: Non Functioning Pancreatic Endocrine Tumor
Breast Cancer, Sarcoma
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
This is a phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining the impact of riluzole therapy on circulating brain derived neuropathic factor (BDNF) levels in cancer survivors (recently…
- Conditions
- Breast Cancer, Sarcoma, Gastric Cancer, Lung Cancer
- Trial name
- NCT06580002
- Testing
- Riluzole
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of California, Irvine
Non Functioning Pancreatic Endocrine Tumor
Long-term Prognosis for Non-functional Neuroendocrine Tumors of the Pancreatic Body and Tail ≤ 3cm
This study aims to quantify the malignant potential of non-functional neuroendocrine tumors of the pancreatic body and tail ≤ 3 cm by collecting real-world data from large pancreatic centers across the country, and to evaluate…
- Trial name
- NCT05907824
- Testing
- Histopathological review, long-term prognosis and quality of life follow-up
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Fudan University
Diagnosis
Nonfunctional Pancreatic NET and PET Imaging
Predicting aggressive behavior in the group of nonfunctional pancreatic neuroendocrine tumors (NF P-NET) remains a difficult problem in clinical practice.
- Trial name
- NCT02621541
- Testing
- PET/CT
- Where
- 2 sites in Finland
- Volunteers
- 20 people
- Sponsor
- Turku University Hospital
Pancreatectomy, Diabetes Mellitus Type 2
Clinical, Oncologic, and Metabolic Effects of Pancreatic Mass Loss After Pancreatectomy in Non-Diabetic Patients
This study will examine how removal of part or all of the pancreas affects blood sugar control, metabolism, and clinical outcomes over time.
- Conditions
- Pancreatectomy, Diabetes Mellitus Type 2, Pancreatic Neoplasms
- Trial name
- DCP-NDM (NCT07608055)
- Where
- Italy
- Volunteers
- 579 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Pancreatic Neuroendocrine Tumors in MEN1
Non-functioning Pancreatic Neuroendocrine Tumors in MEN1: Somatostatin Analogs Versus NO Treatment
A.Background More than 90% of patients with multiple endocrine neoplasia type 1 (MEN1) develop multiple pancreatic neuroendocrine tumors (pNETs). These tumors are the most common cause for premature death in MEN1.
- Trial name
- SANO (NCT02705651)
- Testing
- Somatostatin-Analog
- Volunteers
- 180 people
- Sponsor
- Medical University of Vienna
Advanced Digestive System Neuroendocrine Neoplasm, Duodenal Neuroendocrine Tumor G1
Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin
This phase II trial studies how well ribociclib works in treating patients with neuroendocrine tumors of the foregut, which includes the thymus, lung, stomach, and pancreas, that have spread to other places in the body and…
- Conditions
- Advanced Digestive System Neuroendocrine Neoplasm, Duodenal Neuroendocrine Tumor G1, Functional Pancreatic Neuroendocrine Tumor, Gastric Neuroendocrine Tumor
- Trial name
- NCT02420691
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Ribociclib
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center